Tranzyme Pharma to present clinical results on ulimorelin (TZP-101) at Digestive Disease Week 2010

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
GE Opens First New Manufacturing Operation in Louisville, Ky...
Get set for Bupa Great Birmingham Run...
New Regional Aircraft Contracts and Support...
Harris Corporation's John Shipley Honored by U.S...
Farmers can use red diesel to help out during extreme weather...
Hogan Lovells' It's Not Just Peanuts Campaign Wins Legal Business...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Tranzyme Pharma to present clinical results on ulimorelin (TZP-101) at Digestive Disease Week 2010
Biopharmaceutical company Tranzyme Pharma said on Friday that in May the company will present data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis.
The study results have been selected for oral presentation at Digestive Disease Week (DDW) 2010...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search